A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 545-547

  Marchand, V ^a   Graveleau, J ^b   Lanctin Garcia, C ^b   Bourbouloux, E ^a   Bridji, B ^a   Resche, I ^a   Kraeber Bodere F ^a,c   Rousseau, C ^a,c  

^a Cancer Center   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

FDG PET; Ovarian adenocarcinoma; Paraneoplastic cerebellar degeneration

Indexed keywords

CARBOPLATIN; CELL ANTIBODY; FLUORODEOXYGLUCOSE; PACLITAXEL; UNCLASSIFIED DRUG; YO ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; APPARATUS; ARTICLE; CANCER SURGERY; CASE REPORT; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; OVARY ADENOCARCINOMA; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPTOM;

ADENOCARCINOMA; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PARANEOPLASTIC CEREBELLAR DEGENERATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34247160418     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.01.047     Document Type: Article

References (10)

1. Giannapoulou C. Navigating the paraneoplastic neurological syndromes. Eur. J. Nucl. Med. 30 (2003 (Mar)) 233-338
2. Rees J.H., Hain S.F., Johnson M.R., Hughes R.A., Costa D.C., Ell P.J., et al. The role of 18F-fluoro-2-deoxy-glucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 124 (2001) 2223-2231
3. Shinohara Y., Ohnuki Y., Yoshii F., Takahashi W., Onoe K., and Takagi S. Detection of primary tumor in paraneoplastic cerebellar degeneration by FDG-PET. Ann. Neurol. 43 (1998) 684
4. Antoine J.C., Cinotti L., Tilikete C., Bouhour F., Camdessanche J.P., Confavreux C., et al. 18F-Fluoro-2-deoxy-glucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann. Neurol. 48 (2000) 105-108
5. Rojas I., Graus F., Kime-Guibert F., Rene R., Delattre J.Y., Ramon J.M., et al. Long term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55 (2000) 713-715
6. Cao Y., Abbas J., Wu X., Dooley J., and Van Amburg J. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol. Oncol. 75 (1999) 178-183
7. Sham'sili S., Gretkens J., de Leeuw B., vanden Bent M., Hooijkaas H., van der Holt B., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 123 (2003) 1409-1418
8. Drlicek M., Bianchi G., Bogliun G., Casati B., Grisold W., Kolig C., et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a longterm survey of ovarian cancer patients. J. Neurol. 244 (1997) 85-89
9. Rubello D., Vitaliani R., Rigoni M.T., Rampin L., Giometto B., Casara D., et al. A rare case of paraneoplastic cerebellar degeneration discovered by whole-body F-18 FDG PET. Clin. Nucl. Med. 30 (2005 (Oct)) 704-706
10. Frings M., Antoch G., Knorn P., Freudenberg L., Bier U., Timmann D., et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J. Neurol. 252 2 (2005 (Feb)) 197-201